Explore

Rapid Read Rapid Read
NHS Race and Health Observatory Expands Genomic Testing to Address Ethnic Health Inequalities

NHS Race and Health Observatory Expands Genomic Testing to Address Ethnic Health Inequalities

The NHS Race and Health Observatory has announced the expansion of genomic testing to include DPYD gene variants found in non-European ancestry groups. This initiative aims to address ethnic health inequalities in cancer care by screening for variants that affect the breakdown of fluoropyrimidine chemotherapy. The North West Genomic Laboratory Hub began screening for the c.557A>G variant in September 2025, which is prevalent in people of African ancestry. As a result, three patients have received personalized chemotherapy doses, reducing their risk of adverse drug reactions. The Observatory is also testing for a fifth variant at six other genomic hubs, following a systematic review that called for broader screening.
Rapid Read Rapid Read
Autoimmune Conditions Linked to Mental Illness: New Screening Efforts in New York

Autoimmune Conditions Linked to Mental Illness: New Screening Efforts in New York

Researchers at Columbia University are undertaking a project to screen individuals in New York state's psychiatric hospitals for biomarkers of autoimmune, metabolic, or genetic underpinnings of mental health conditions. This initiative aims to identify cases where autoimmune conditions may be driving mental illness, offering alternative treatment options. The project follows findings that antibodies attacking the brain can lead to conditions like schizophrenia and OCD, challenging traditional views on mental health.
Rapid Read Rapid Read
University of Pennsylvania Develops Blood Test to Predict Kidney Failure Risk in Black Americans

University of Pennsylvania Develops Blood Test to Predict Kidney Failure Risk in Black Americans

Researchers at the University of Pennsylvania's Perelman School of Medicine have developed a groundbreaking blood test that can predict the risk of kidney failure in individuals of African ancestry who carry high-risk variants of the APOL1 gene. This test, published in Nature Medicine, identifies those at risk long before traditional clinical signs appear. Chronic kidney disease disproportionately affects African American populations, with specific APOL1 gene variants increasing susceptibility to kidney damage. The new test uses a panel of circulating proteins as biomarkers to forecast the likelihood of progression to end-stage renal failure, surpassing existing clinical models. The study involved over 850 African ancestry individuals, revealing that those in the highest risk tier faced a significantly higher rate of renal failure within ten years.
Rapid Read Rapid Read
Michael J. Fox Foundation Collaborates with Biognosys on Parkinson's Biomarker Project

Michael J. Fox Foundation Collaborates with Biognosys on Parkinson's Biomarker Project

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has partnered with Swiss biotech company Biognosys to focus on the biomarker LRRK2, which is a significant target in Parkinson's disease drug discovery. This collaboration aims to develop quantitative biomarker assays that could guide therapy development and identify patients suitable for LRRK2-directed treatments. LRRK2 has become a compelling target due to its excessive activity in Parkinson's disease, but the lack of assays has hindered progress. Denali Therapeutics' DNL151, a small-molecule LRRK2 inhibitor, is currently in phase 2b clinical trials, with results expected later this year. Other companies like Neuron23, Oncodesign Precision Medicines, and Brenig Therapeutics are also developing LRRK2-targeted therapies.
Trendline Trendline
4D Path and Daiichi Sankyo Collaborate to Enhance AI-Driven Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate to Enhance AI-Driven Biomarkers for Cancer Treatment

4D Path and Daiichi Sankyo Collaborate to Enhance AI-Driven Biomarkers for Cancer Treatment
Trendline Trendline
Caristo Diagnostics Appoints Stephen Deitsch as CEO Amidst Strategic Growth

Caristo Diagnostics Appoints Stephen Deitsch as CEO Amidst Strategic Growth

Caristo Diagnostics Appoints Stephen Deitsch as CEO Amidst Strategic Growth
Rapid Read Rapid Read
Dutch Study Highlights Benefits of Off-Label Targeted Cancer Therapies for Patients

Dutch Study Highlights Benefits of Off-Label Targeted Cancer Therapies for Patients

A Dutch study has revealed that off-label targeted cancer therapies can significantly benefit patients, as demonstrated in the Dutch multicenter DRUP trial. This trial, which included over 1600 patients, aimed to expand the use of existing drugs beyond their approved indications to provide more personalized treatment options. The results, published in Nature, show that about one-third of the participants responded positively to the treatment or maintained stable disease for at least four months. The trial also identified 67 exceptional responders who showed complete response or remained progression-free for at least two years. The study underscores the potential of these targeted drugs to deliver substantial benefits, even for heavily pretreated, difficult-to-treat, or rare cancers.
Rapid Read Rapid Read
ClearNote Health to Present Advanced Pancreatic Cancer Detection Test at AACR 2026

ClearNote Health to Present Advanced Pancreatic Cancer Detection Test at AACR 2026

ClearNote Health, a company focused on early cancer detection, is set to present its Avantect® Pancreatic Cancer Test at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The test, which utilizes the company's Virtuoso™ epigenomics platform, offers a noninvasive method to detect pancreatic cancer with a sensitivity of 82.6% and specificity of 97.5%. This technology measures active biological differences between cancerous and healthy cells using a blood sample. The test is particularly aimed at high-risk groups, such as those with genetic predispositions or a family history of pancreatic cancer. ClearNote Health will also present data on the use of cell-free DNA-based epigenomic profiling to predict treatment responses, which could lead to the development of new blood-based biomarkers.
Rapid Read Rapid Read
3D Bioprinting and Photoacoustic Microscopy Enhance Cancer Drug Testing

3D Bioprinting and Photoacoustic Microscopy Enhance Cancer Drug Testing

Recent advancements in precision medicine have been highlighted through the integration of 3D bioprinting and photoacoustic microscopy (PAM) to evaluate anti-cancer drug efficacy. This innovative approach involves creating bioprinted tumor-vessel models that mimic the human tumor microenvironment. The study utilizes a custom-made high-resolution PAM system to investigate the effects of anti-cancer drugs on these models. By employing a pulsed laser for excitation, the system provides enhanced imaging depth and resolution, allowing for detailed observation of angiogenic responses and drug effects. The research demonstrates that this platform can effectively simulate tumor-induced angiogenesis and assess the impact of drugs like temozolomide and sunitinib, both individually and in combination, on vascular growth and tumor progression.
Trendline Trendline
Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease Diagnosis

Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease Diagnosis

Bracco Supports ASNC's Endorsement of Cardiac PET for Coronary Artery Disease Diagnosis
Rapid Read Rapid Read
Gut Microbiota Identified as Potential Biomarker for Rectal Cancer Treatment Response

Gut Microbiota Identified as Potential Biomarker for Rectal Cancer Treatment Response

A systematic review has identified specific gut microbiota as potential biomarkers for predicting the response to neoadjuvant treatment in rectal cancer patients. The review, which synthesized data from 16 observational studies involving 842 patients, found that certain microbial taxa, such as Bacteroides, Fusobacterium, and Akkermansia, are consistently associated with poor response to neoadjuvant chemoradiotherapy (nCRT). The studies utilized various methods, including 16S rRNA sequencing and metagenomics, to analyze microbiota composition. Despite promising findings, the review highlights the need for standardized validation due to methodological heterogeneity and limited reproducibility.
Rapid Read Rapid Read
AI Tool Developed to Optimize Bowel Cancer Treatment and Reduce Unnecessary Side Effects

AI Tool Developed to Optimize Bowel Cancer Treatment and Reduce Unnecessary Side Effects

Scientists from the Institute of Cancer Research in London and the RCSI University of Medicine and Health Sciences in Dublin have developed an AI tool called PhenMap. This tool is designed to identify colorectal cancer (CRC) patients who are most likely to benefit from the drug bevacizumab, which has recently been approved for NHS use in treating metastatic CRC. The AI analyzes genetic data and other clinical information to score patients based on their likelihood of benefiting from the drug, which is known to cause serious side effects in some patients. The research, published in Scientific Reports, aims to improve treatment outcomes and reduce unnecessary side effects by targeting the drug to patients who will benefit the most.